Shares of ORIC Pharmaceuticals, Inc. (ORIC) are surging more than 17% Monday morning after the company announced about $85 million private placement financing.
ORIC said that a Group of institutional and healthcare specialist investors have agreed to buy 12.1 million shares, or pre-funded warrants in lieu thereof, of the company for $7 per share, a premium of about 8% to the closing price on June 23.
The pre-funded warrants will have an exercise price of $0.0001 per share of common stock, will be immediately exercisable, and will remain exercisable until exercised in full, the company said.
The financing is expected to close on June 27.
Pro forma cash and investments are expected to fund current operating plan into late 2025, ORIC added.
"As the competitive profiles of multiple of our clinical programs begin to emerge with respect to internally generated data and competitor updates, the added financial firepower provided by this blue-chip syndicate of investors, both new and existing and with whom we've had longstanding relationships, allows us to aggressively advance our pipeline for the benefit of patients," said Jacob M. Chacko, chief executive officer.
ORIC, currently at $7.50, touched a new high of 7.65 this morning.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.